PATENT CLAIM ANALYSIS

Application Number: 16425826
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-09
Patent Classification: ["514", "04400A"]

Abstract:
The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.

Claim (Index 41):
The method of  claim 33  wherein the MCL-1 priming is at least 20%.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 100.0
- Lexical Diversity: 1.22727
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16132270', '15134051', '16023360', '16279623', '15033810']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7924655831592384
- 35 USC 102 Novelty (BERT): 0.7257363588806951
- Combined Prediction Score: 0.7857926607313841
- Mean Citation Score: 505.629656
- Max Citation Score: 791.6268
- Similarity Product: 601.8523245212318

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test